Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348600 | 0.82 | PDCD1LG2 (0.37) | CRBNDDB1 | |
| SCHEMBL29348586 | 0.76 | CRBN (0.35) | CRBNDDB1 | |
| SCHEMBL31068247 | 0.76 | CRBN (0.35) | CRBNDDB1 | |
| SCHEMBL29348671 | 0.74 | CRBN (0.39) | CRBNDDB1 | |
| SCHEMBL29348961 | 0.74 | CRBN (0.37) | CRBNDDB1 | |
| SCHEMBL31101094 | 0.63 | CRBN (0.46) | CRBNDDB1 | |
| SCHEMBL29348715 | 0.62 | CRBN (0.39) | CRBNDDB1 | |
| SCHEMBL26049154 | 0.62 | CRBN (0.43) | CRBNDDB1 | |
| SCHEMBL31101130 | 0.61 | CRBN (0.49) | CRBNDDB1 | |
| SCHEMBL31099982 | 0.61 | CRBN (0.46) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |